Siamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium
Siamab Therapeutics, Inc., a biotechnology company developing novel cancer immunotherapies, today announced new pre-clinical data that showed its novel ST1 antibody drug conjugates (ADCs) target chemoresistant ovarian cancer cells and demonstrate strong efficacy in ovarian cancer models. These data were presented at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium 2016 in Seattle, Wash., on Monday, Sept. 12, 2016. Read more >>